Adaptive Biotechnologies Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
ADPT$29.36-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue | $93,973 | $46,435 | $205,295 | $131,498 |
| Operating expenses | ||||
| Cost of revenue | 18,157 | 16,667 | 53,135 | 54,035 |
| Research and development | 23,669 | 24,163 | 72,006 | 79,761 |
| Sales and marketing | 23,470 | 20,551 | 70,090 | 63,184 |
| General and administrative | 17,959 | 17,258 | 53,144 | 54,750 |
| Amortization of intangible assets | 428 | 428 | 1,270 | 1,275 |
| Impairment of long-lived assets | — | — | — | 7,205 |
| Total operating expenses | 83,683 | 79,067 | 249,645 | 260,210 |
| Income (loss) from operations | 10,290 | (32,632) | (44,350) | (128,712) |
| Interest and other income, net | 2,226 | 3,474 | 7,296 | 11,462 |
| Interest expense | (2,971) | (2,939) | (8,824) | (8,628) |
| Net income (loss) | 9,545 | (32,097) | (45,878) | (125,878) |
| Add: Net loss (income) attributable to noncontrolling interest | 1 | 26 | (42) | 78 |
| Net income (loss) attributable to Adaptive Biotechnologies Corporation | $9,546 | $(32,071) | $(45,920) | $(125,800) |
| Net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | $0.06 | $(0.22) | $(0.30) | $(0.86) |
| Weighted-average shares used in computing net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders | ||||
| Basic | 152,432,307 | 147,516,398 | 151,248,398 | 146,908,234 |
| Diluted | 163,162,107 | 147,516,398 | 151,248,398 | 146,908,234 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.